Literature DB >> 8658370

Evaluation of the beta 2 adrenoceptor agonist/antagonist activity of formoterol and salmeterol.

A Grove1, B J Lipworth.   

Abstract

BACKGROUND: Salmeterol and formoterol have a lower intrinsic activity at beta 2 receptors than isoprenaline in human bronchus in vitro. The aim of the present study was to evaluate in vivo the beta 2 agonist/antagonist activity of salmeterol and formoterol at rest with low endogenous adrenergic tone, on exercise with raised endogenous adrenergic tone, and in the presence of fenoterol, an exogenous full beta 2 receptor agonist.
METHODS: Eight normal subjects were randomised to receive single doses of placebo, salmeterol 300 micrograms, formoterol 72 micrograms, or propranolol 80 mg at weekly intervals. beta 2 adrenoceptor responses were evaluated at rest, at peak exercise, and after treatment with fenoterol 2.4 mg.
RESULTS: At rest salmeterol and formoterol exhibited equivalent beta 2 agonist activity with regard to decrease in serum potassium levels and increase in finger tremor, with propranolol having no effect. Salmeterol and formoterol, like propranolol, potentiated the hyperkalaemic delta response to exercise compared with placebo, consistent with beta 2 antagonism: (mean difference and 95% confidence interval (CI) compared with placebo) salmeterol 0.20 (0.02 to 0.38) mmol/l, formoterol 0.17 (0.00 to 0.34) mmol/l, propranolol 0.45 (0.08 to 0.82) mmol/l. Propranolol blunted the heart rate delta response to exercise, consistent with beta 1 blockade, whilst salmeterol and formoterol had no effect. Salmeterol and formoterol, like propranolol, attenuated the hypokalaemic, tremor, and heart rate delta responses to fenoterol compared with placebo, in keeping with beta 2 blockade: potassium, salmeterol 0.18 (0.0 to 0.36) mmol/l, formoterol 0.17 (-0.03 to 0.37) mmol/l, propranolol 0.80 (0.54 to 1.06) mmol/l; tremor, salmeterol -0.69 (-1.26 to -0.12) log units, formoterol -0.71 (-1.53 to 0.11) log units, propranolol -0.85 (-1.66 to -0.04) log units; heart rate, salmeterol -6 (-13 to 1) beats/min, formoterol -10 (-19 to -1) beats/min, propranolol -18 (-29 to -7) beats/min.
CONCLUSIONS: At rest with low endogenous adrenergic tone salmeterol and formoterol showed equivalent beta 2 mediated agonist activity in terms of serum potassium and finger tremor responses. In the presence of raised endogenous adrenergic tone at peak exercise and in the presence of fenoterol (an exogenous full beta 2 receptor agonist), salmeterol and formoterol, like propranolol, exhibited beta 2 receptor antagonism as evidenced by their attenuation of beta 2 receptor mediated responses. The degree of beta 2 blockade with formoterol and salmeterol was comparable but less than with propranolol. The relevance of these findings at extrapulmonary beta 2 receptors with regard to airway beta 2 responses remains unclear and warrants further investigation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8658370      PMCID: PMC472800          DOI: 10.1136/thx.51.1.54

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  15 in total

Review 1.  Beta-adrenoceptor partial agonists: a renaissance in cardiovascular therapy?

Authors:  D G Waller
Journal:  Br J Clin Pharmacol       Date:  1990-08       Impact factor: 4.335

2.  Evidence that the efficacy (intrinsic activity) of fenoterol is higher than that of salbutamol on beta-adrenoceptors in guinea-pig trachea.

Authors:  S R O'Donnell; J C Wanstall
Journal:  Eur J Pharmacol       Date:  1978-02-01       Impact factor: 4.432

3.  Beta-adrenoceptor responses to inhaled salbutamol in normal subjects.

Authors:  B J Lipworth; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

4.  Assessment of airways, tremor and chronotropic responses to inhaled salbutamol in the quantification of beta 2-adrenoceptor blockade.

Authors:  B J Lipworth; R A Brown; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1989-07       Impact factor: 4.335

5.  Beta-adrenoceptor subtypes in human, rat, guinea pig, and rabbit atria.

Authors:  C Wilson; C Lincoln
Journal:  J Cardiovasc Pharmacol       Date:  1984 Nov-Dec       Impact factor: 3.105

6.  In vitro responsiveness of human asthmatic bronchus to carbachol, histamine, beta-adrenoceptor agonists and theophylline.

Authors:  R G Goldie; D Spina; P J Henry; K M Lulich; J W Paterson
Journal:  Br J Clin Pharmacol       Date:  1986-12       Impact factor: 4.335

7.  Effects of the beta 2-adrenoceptor antagonist ICI 118,551 on exercise tachycardia and isoprenaline-induced beta-adrenoceptor responses in man.

Authors:  J M Arnold; P C O'Connor; J G Riddell; D W Harron; R G Shanks; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1985-05       Impact factor: 4.335

8.  Expression of the beta 2 adrenoceptor partial agonist/antagonist activity of salbutamol in states of low and high adrenergic tone.

Authors:  A Grove; L C McFarlane; B J Lipworth
Journal:  Thorax       Date:  1995-02       Impact factor: 9.139

9.  Catecholamine modulation of rapid potassium shifts during exercise.

Authors:  M E Williams; E V Gervino; R M Rosa; L Landsberg; J B Young; P Silva; F H Epstein
Journal:  N Engl J Med       Date:  1985-03-28       Impact factor: 91.245

10.  Digitalis enhances exercise-induced hyperkalaemia.

Authors:  A Nørgaard; H E Bøtker; N A Klitgaard; P Toft
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

View more
  7 in total

1.  Effects of prior treatment with salmeterol and formoterol on airway and systemic beta 2 responses to fenoterol.

Authors:  A Grove; B J Lipworth
Journal:  Thorax       Date:  1996-06       Impact factor: 9.139

Review 2.  Dose-response of inhaled drugs in asthma. An update.

Authors:  D J Clark; B J Lipworth
Journal:  Clin Pharmacokinet       Date:  1997-01       Impact factor: 6.447

3.  Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists.

Authors:  H J van der Woude; T H Winter; R Aalbers
Journal:  Thorax       Date:  2001-07       Impact factor: 9.139

Review 4.  Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma.

Authors:  R A Bartow; R N Brogden
Journal:  Drugs       Date:  1998-02       Impact factor: 9.546

5.  Comparison of combination inhalers vs inhaled corticosteroids alone in moderate persistent asthma.

Authors:  Daniel K C Lee; Catherine M Jackson; Graeme P Currie; Wendy J Cockburn; Brian J Lipworth
Journal:  Br J Clin Pharmacol       Date:  2003-11       Impact factor: 4.335

6.  Cross tolerance to salbutamol occurs independently of beta2 adrenoceptor genotype-16 in asthmatic patients receiving regular formoterol or salmeterol.

Authors:  D K C Lee; C M Jackson; C E Bates; B J Lipworth
Journal:  Thorax       Date:  2004-08       Impact factor: 9.139

Review 7.  Second-line controller therapy for persistent asthma uncontrolled on inhaled corticosteroids: the step 3 dilemma.

Authors:  Brian J Lipworth; Catherine M Jackson
Journal:  Drugs       Date:  2002       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.